• Explore /
  • Poster
  • / First-in-human study of RLY-2608, a pan-mutant and isoform selective PI3Kα inhibitor, as a single agent in patients (pts) with advanced solid tumors and in combination with fulvestrant in pts with advanced breast cancer.

First-in-human study of RLY-2608, a pan-mutant and isoform selective PI3Kα inhibitor, as a single agent in patients (pts) with advanced solid tumors and in combination with fulvestrant in pts with advanced breast cancer.

Abstract Poster

Authors

Cristina Saura

Cristina Saura

Vall d’Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain

Cristina Saura , Lucia Sanz , Janice Kim , Komal L. Jhaveri , Angel Guerrero , Pablo Tolosa Ortega , Anne F. Schott , Giuseppe Curigliano , Cesar Augusto Perez , Rita Nanda , Erika P. Hamilton , Jason Timothy Henry , Kari Braun Wisinski , Sarah L Sammons , Jennifer Margaret Segar , Santiago Ponce Aix , Milana Bergamino Sirvén , Alexander I. Spira , Alison M. Schram , Andreas Varkaris

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Hormone Receptor-Positive

Clinical Trial Registration Number

NCT05216432

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr TPS1128)

DOI

10.1200/JCO.2024.42.16_suppl.TPS1128

Abstract #

TPS1128

Poster Bd #

102a

Abstract Disclosures

Similar Posters

First Author: Philippe L. Bedard

First Author: Virginia F. Borges

First Author: Cesar Augusto Perez

First Author: Alison M. Schram